Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 9:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 475 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 5 Azacytidine Clear all
Terminated Phase 1 Interventional

Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia

NCT04172844
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Azacitidine, Venetoclax, Pevonedistat
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Rochester, Minnesota • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 1 Interventional

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

NCT01460498
View directory record Official record
Conditions
Leukemia
Interventions
Azacitidine (AZA), Tyrosine kinase inhibitor (TKI), Azacitidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 1 Interventional

MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

NCT00101179
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Leukemia, Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Azacitidine, Entinostat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Sep 9, 2026, 9:22 PM EDT
Active, not recruiting Phase 1 Interventional

Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

NCT06445907
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Venetoclax, Q702
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

NCT00760084
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Decitabine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 7, 2011 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 1 Interventional Results available

Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide

NCT00629343
View directory record Official record
Conditions
Soft Tissue Sarcoma, Mesothelioma
Interventions
Azacitidine, Temozolomide
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 1 Interventional

A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy

NCT03298516
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
DCLL9718S, Azacitidine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Duarte, California • Aurora, Colorado • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 1 Interventional

PRO#0118: Decitabine Plus Mini Flu-Bu

NCT01455506
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Decitabine plus Fludarabine and Busulfan
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
45 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT01892371
View directory record Official record
Conditions
FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Azacitidine, Cytarabine, Quizartinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS

NCT02018926
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Mocetinostat, Azacitidine
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Miami Lakes, Florida • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 9, 2026, 9:22 PM EDT
Recruiting Phase 2 Interventional

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

NCT05442216
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Tagraxofusp, Azacitidine, Venetoclax
Drug
Lead sponsor
Joshua Zeidner
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
7
States / cities
Miami, Florida • Orlando, Florida • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 9, 2026, 9:22 PM EDT
Terminated Phase 2 Interventional Results available

Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS

NCT01442714
View directory record Official record
Conditions
Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Interventions
Azacitidine, Lenalidomide
Drug
Lead sponsor
Stanford University
Other
Eligibility
60 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects

NCT03828084
View directory record Official record
Conditions
Healthy
Interventions
Decitabine
Drug
Lead sponsor
EpiDestiny, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 9, 2026, 9:22 PM EDT
Terminated Phase 2 Interventional Results available

Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma

NCT00561912
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Decitabine, Interferon Alfa-2b
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2011 · Synced Sep 9, 2026, 9:22 PM EDT
Terminated Phase 1 Interventional Results available

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

NCT02675452
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia
Interventions
AMG 176, Azacitidine, Itraconazole
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
10
States / cities
Duarte, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Sep 9, 2026, 9:22 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

NCT03240211
View directory record Official record
Conditions
PTCL, CTCL
Interventions
Pembrolizumab, Pralatrexate, Decitabine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 90 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 9, 2026, 9:22 PM EDT
Recruiting Phase 2 Interventional

Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy

NCT07434492
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Smart Ankle-Foot Orthosis, 5-Azacitidine, Placebo
Device · Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
8 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 9, 2026, 9:22 PM EDT
Terminated Phase 1Phase 2 Interventional

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

NCT04113616
View directory record Official record
Conditions
Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
Interventions
KRT-232, Cytarabine, Decitabine
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Chicago, Illinois • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers

NCT00751699
View directory record Official record
Conditions
Healthy
Interventions
Asacol, Lialda
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 9, 2026, 9:22 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT02890329
View directory record Official record
Conditions
Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Decitabine, Ipilimumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
11
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 9, 2026, 9:22 PM EDT
Terminated Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

NCT02319369
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Milademetan, AZA
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Duarte, California • San Francisco, California • Fairway, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

NCT03306264
View directory record Official record
Conditions
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Interventions
ASTX727, Dacogen
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
39
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

NCT01093573
View directory record Official record
Conditions
Untreated Adult Acute Myeloid Leukemia
Interventions
midostaurin, azacitidine, bone marrow aspiration, mutation analysis, Pharmacokinetic study
Drug · Other
Lead sponsor
Brenda Cooper, MD
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Cleveland, Ohio • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

NCT01869114
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), de Novo Myelodysplastic Syndromes, Myelodysplastic Syndrome With Isolated Del(5q), Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia
Interventions
Sirolimus, Azacitidine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
5
States / cities
Sewell, New Jersey • Abington, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 9, 2026, 9:22 PM EDT